ZVSA vs. SEEL, SNGX, EVOK, ENSC, GOVX, PTPI, CYCC, ALZN, XCUR, and BCEL
Should you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Seelos Therapeutics (SEEL), Soligenix (SNGX), Evoke Pharma (EVOK), Ensysce Biosciences (ENSC), GeoVax Labs (GOVX), Petros Pharmaceuticals (PTPI), Cyclacel Pharmaceuticals (CYCC), Alzamend Neuro (ALZN), Exicure (XCUR), and Atreca (BCEL). These companies are all part of the "pharmaceutical preparations" industry.
ZyVersa Therapeutics (NASDAQ:ZVSA) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.
ZyVersa Therapeutics has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
Seelos Therapeutics received 68 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote.
In the previous week, Seelos Therapeutics had 1 more articles in the media than ZyVersa Therapeutics. MarketBeat recorded 6 mentions for Seelos Therapeutics and 5 mentions for ZyVersa Therapeutics. Seelos Therapeutics' average media sentiment score of 0.01 beat ZyVersa Therapeutics' score of -0.78 indicating that Seelos Therapeutics is being referred to more favorably in the news media.
3.9% of ZyVersa Therapeutics shares are owned by institutional investors. Comparatively, 23.4% of Seelos Therapeutics shares are owned by institutional investors. 0.7% of ZyVersa Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Seelos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
ZyVersa Therapeutics has a net margin of 0.00% compared to Seelos Therapeutics' net margin of -1,373.61%. Seelos Therapeutics' return on equity of 0.00% beat ZyVersa Therapeutics' return on equity.
ZyVersa Therapeutics currently has a consensus target price of $120.00, indicating a potential upside of 2,574.27%. Seelos Therapeutics has a consensus target price of $360.00, indicating a potential upside of 18,846.37%. Given Seelos Therapeutics' higher possible upside, analysts plainly believe Seelos Therapeutics is more favorable than ZyVersa Therapeutics.
Seelos Therapeutics has higher revenue and earnings than ZyVersa Therapeutics.
Summary
Seelos Therapeutics beats ZyVersa Therapeutics on 10 of the 14 factors compared between the two stocks.
Get ZyVersa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZVSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ZyVersa Therapeutics Competitors List
Related Companies and Tools
